Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars

Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars

Linked Content This article is linked to Goncalves et al papers. To view these articles visit https://doi.org/10.1111/apt.14808 and https://doi.org/10.1111/apt.14860.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2018-09, Vol.48 (5), p.574-575
Hauptverfasser: Pouillon, L., Allocca, M., Peyrin‐Biroulet, L.
Format: Artikel
Sprache:eng
Schlagworte:
Epitopes
Infliximab
Monoclonal antibodies
Tumor necrosis factor-α
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Linked Content This article is linked to Goncalves et al papers. To view these articles visit https://doi.org/10.1111/apt.14808 and https://doi.org/10.1111/apt.14860.
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.14847